Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its molecular thyroid tests have received coverage for 3.8 million patients living in the Northeastern US from Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ).

The payor has agreed to cover Interpace's ThyGenX and ThyraMir tests, effective Jan. 9, 2018, for thyroid nodules deemed indeterminate by standard cytopathological analysis, Interpace said. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.